The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with ...

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer (NYSE: PFE) ...

"We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer ...